Research Article
Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients
Table 4
Absolute changes in HMGB1, BASDAI, BASFI, ASDAS-ESR, ASDAS-CRP, ESR, and CRP in the two follow-up therapeutic AS groups.
| | Anti-TNF | SASP + NSAIDs |
| HMGB1 change, mean (SD), ng/mL | | | 1 month | (22.25) | 1.52 (24.99) | 3 months | (23.70) | (19.89) | 6 months | (28.68) | (25.30) |
| BASDAI change, mean (SD) | | | 1 month | (1.51) | (0.51) | 3 months | (1.61) | (0.77) | 6 months | (1.51) | (1.16) |
| BASFI change, mean (SD) | | | 1 month | (1.56) | (0.61) | 3 months | (1.65) | (1.00) | 6 months | (1.69) | (1.17) |
| ASDAS-ESR change, mean (SD) | | | 1 month | (1.07) | (0.59) | 3 months | (0.86) | (0.62) | 6 months | (0.89) | (0.69) |
| ASDAS-CRP change, mean (SD) | | | 1 month | (0.79) | (0.81) | 3 months | (0.83) | (1.00) | 6 months | (0.63) | (0.96) |
| ESR change, mean (SD), mm/h | | | 1 month | (24.61) | (19.22) | 3 months | (25.91) | (18.18) | 6 months | (26.69) | (22.47) |
| CRP change, mean (SD), mg/L | | | 1 month | (12.99) | (18.54) | 3 months | (25.99) | (25.57) | 6 months | (28.41) | (26.32) |
|
|
versus baseline. versus SASP + NSAIDs.
|